BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37401138)

  • 21. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series.
    Amagai R; Kambayashi Y; Ohuchi K; Furudate S; Hashimoto A; Asano Y; Fujimura T
    Dermatol Ther; 2022 Nov; 35(11):e15858. PubMed ID: 36161437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.
    Lewis NE; Gao Q; Petrova-Drus K; Pulitzer M; Sigler A; Baik J; Moskowitz AJ; Horwitz SM; Dogan A; Roshal M
    Cytometry B Clin Cytom; 2022 May; 102(3):189-198. PubMed ID: 35451196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.
    Gibson JF; Huang J; Liu KJ; Carlson KR; Foss F; Choi J; Edelson R; Hussong JW; Mohl R; Hill S; Girardi M
    J Am Acad Dermatol; 2016 May; 74(5):870-7. PubMed ID: 26874819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
    Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
    Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
    Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
    Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
    Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.
    Roberts AA; Amano M; Felten C; Galvan M; Sulur G; Pinter-Brown L; Dobbeling U; Burg G; Said J; Baum LG
    Mod Pathol; 2003 Jun; 16(6):543-51. PubMed ID: 12808059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.
    Masuda Y; Tatsuno K; Kitano S; Miyazawa H; Ishibe J; Aoshima M; Shimauchi T; Fujiyama T; Ito T; Tokura Y
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1456-1460. PubMed ID: 29341283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
    Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
    J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mogamulizumab-associated rash: A challenging case report and literature review.
    Martínez-Fernández S; Suh-Oh HJ; Couselo-Rodríguez C; Soto-García D; Álvarez C; Flórez Á
    Australas J Dermatol; 2023 May; 64(2):e191-e193. PubMed ID: 36896897
    [No Abstract]   [Full Text] [Related]  

  • 39. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics.
    Horna P; Wang SA; Wolniak KL; Psarra K; Almeida J; Illingworth AJ; Johansson U; Craig FE; Torres R
    Cytometry B Clin Cytom; 2021 Mar; 100(2):142-155. PubMed ID: 32319723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.